Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 8/20 | 0.78 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.78 |
| ▸ | SULT2A1 | Q06520 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.32 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905471 | 1.00 | TNKS (0.78) | TNKSTNKS2SULT2A1DYRK1ABCHE | |
| SCHEMBL9905439 | 0.88 | TNKS (1.00) | TNKSTNKS2SULT2A1 | |
| SCHEMBL9905440 | 0.88 | TNKS (1.00) | TNKSTNKS2SULT2A1 | |
| SCHEMBL15449840 | 0.87 | TNKS (0.74) | TNKSTNKS2SULT2A1BCHEACHE | |
| SCHEMBL9905264 | 0.79 | TNKS (0.49) | TNKSTNKS2SULT2A1DYRK1AGRM7 | |
| SCHEMBL9905260 | 0.79 | TNKS (0.49) | TNKSTNKS2SULT2A1DYRK1AGRM7 | |
| SCHEMBL15449823 | 0.79 | TNKS (0.83) | TNKSTNKS2SULT2A1 | |
| SCHEMBL9905415 | 0.79 | TNKS (0.83) | TNKSTNKS2SULT2A1PTGS2 | |
| SCHEMBL9905412 | 0.79 | TNKS (0.83) | TNKSTNKS2SULT2A1PTGS2 | |
| SCHEMBL9905131 | 0.79 | TNKS (0.46) | TNKSTNKS2SULT2A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| EP-2649063-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | Oslo University Hospital HF (NO) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | TNKS 118/4885TNKS2 167/4885SULT2A1 1173/4885 |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | TNKS 145/4885TNKS2 191/4885SULT2A1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.